|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Table 1. Demographic clinical and exposure characteristics of the SAMPA study cohorts | | | | | | | | | | | | | | | | | | | | | | | | |
|  | Cohort | | | | | | | | | | | | | | | | | | | | | | | |
|  | DIVIDS (India) | | | | SAM (Zambia) | | | | CLHNS (Philippines) | | | | CICADA (Tanzania) | | | | NUSTART (Zambia) | | | | St-ATT (Philippines) | | | |
|  | NPM | | PM | | NPM | | PM | | NPM | | PM | | NPM | | PM | | NPM | | PM | | NPM | | PM | |
|  | 54.0 |  | 253.0 |  | 45.0 |  | 58.0 |  | 196.0 |  | 106.0 |  | 569.0 |  | 298.0 |  | 87.0 |  | 195.0 |  | 150.0 |  | 111.0 |  |
| Age | 11.8 | (1.4) | 13.9 | (0.8) | 13.2 | (2.0) | 12.2 | (1.0) | 39.0 | (0.4) | 38.8 | (0.5) | 47.4 | (11.0) | 49.2 | (10.4) | 39.9 | (12.6) | 45.3 | (7.5) | 52.2 | (13.8) | 47.8 | (16.4) |
| Female | 25.0 | (46.3) | 125.0 | (49.4) | 25.0 | (55.6) | 30.0 | (51.7) | 72.0 | (36.7) | 38.0 | (35.8) | 345.0 | (60.6) | 156.0 | (52.3) | 75.0 | (86.2) | 111.0 | (56.9) | 49.0 | (32.7) | 33.0 | (29.7) |
| HIV Seropositive | 0.0 | (.) | 0.0 | (.) | 0.0 | (0.0) | 2.0 | (3.4) | 0.0 | (.) | 0.0 | (.) | 293.0 | (53.3) | 238.0 | (81.2) | 39.0 | (45.3) | 195.0 | (100.0) | 1.0 | (50.0) | 0.0 | (.) |
| Average weight (kg) | 35.3 | (13.4) | 40.6 | (9.4) | 40.1 | (11.6) | 35.3 | (7.5) | 72.1 | (14.2) | 63.7 | (13.0) | 66.4 | (13.6) | 54.5 | (9.1) | 68.6 | (17.3) | 55.1 | (9.9) | 57.4 | (9.9) | 45.6 | (7.3) |
| With CT Scan | 0.0 | (0.0) | 0.0 | (0.0) | 0.0 | (0.0) | 0.0 | (0.0) | 50.0 | (25.5) | 50.0 | (47.2) | 8.0 | (1.4) | 14.0 | (4.7) | 28.0 | (32.2) | 41.0 | (21.0) | 63.0 | (42.0) | 37.0 | (33.3) |
| With Ultrasound | 54.0 | (100.0) | 251.0 | (99.2) | 36.0 | (80.0) | 46.0 | (79.3) | 186.0 | (94.9) | 104.0 | (98.1) | 242.0 | (42.5) | 172.0 | (57.7) | 85.0 | (97.7) | 185.0 | (94.9) | 149.0 | (99.3) | 111.0 | (100.0) |
| With Faecal Elastase | 21.0 | (38.9) | 97.0 | (38.3) | 38.0 | (84.4) | 45.0 | (77.6) | 188.0 | (95.9) | 103.0 | (97.2) | 543.0 | (95.4) | 277.0 | (93.0) | 75.0 | (86.2) | 166.0 | (85.1) | 143.0 | (95.3) | 104.0 | (93.7) |
| EPI | 2.0 | (9.5) | 16.0 | (16.5) | 21.0 | (55.3) | 33.0 | (73.3) | 22.0 | (11.7) | 16.0 | (15.5) | 248.0 | (45.7) | 114.0 | (41.2) | 18.0 | (24.0) | 59.0 | (35.5) | 35.0 | (24.5) | 14.0 | (13.5) |
| Variable distributions are reported as n(%) unless otherwise specified. Where the denominator is less than shown at the column head it is given per cell HIV status NT not tested status unknown for DIVIDS St-ATT CLHNS HIV status was known for most tested for all African participants. Diabetes was defined as 2-hour plasma glucose from oral glucose tolerance (OGTT) ≥11.1 mmol/L and /or HbA1c ≥6.5% USS ultrasound CT CT Scan NPM Not Previously Malnourished PM Previously Malnourished | | | | | | | | | | | | | | | | | | | | | | | | |